ArticleStem cell research & therapy2025
Interleukin 10 enhances endothelial progenitor cell-mediated angiogenesis in extrahepatic portal venous obstruction.
Article in Stem cell research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
objectivesIn this study, the therapeutic potential of endothelial progenitor cells (EPCs) in restoring portal vein blood flow in a rat model of extrahepatic portal venous obstruction (EHPVO) was investigated, and the underlying mechanisms were explored.
methodsRats were divided into normal control (NC), EHPVO, EPC, knockout control-EPC (KO-NC-EPC), and knockout IL-10-EPC (KO-IL-10-EPC) groups. Portal blood flow was measured using a flowmeter. The numbers of blood capillaries and changes in portal vein diameter were analyzed using HE staining. RT-qPCR, Western blotting, and ELISA were employed to assess the relative cytokine levels in portal venous blood and liver tissues.
resultsCompared with the NC group, the EHPVO group exhibited significantly reduced portal blood flow, increased blood capillary density, a higher portal vein diameter ratio, decreased IL-10, eNOS, and t-PA levels, and increased PAI-1 and VEGF levels. EPC administration recovered the EHPVO rats but increased the VEGF level. Injecting the KO-IL-10-EPCs reduced the function of the EPCs in the EHPVO rats.
conclusionsThe results of this study demonstrate that EPCs can effectively ameliorate EHPVO through promoting neovascularization through the upregulation of VEGF expression induced by IL-10.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.